Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial

Sammy Huygens, Quincy Hofsink, Inger S Nijhof, Abraham Goorhuis, Arnon P Kater, Peter Aw Te Boekhorst, Francis Swaneveld, Věra Mj Novotný, Susanne Bogers, Matthijs Ra Welkers, Grigorios Papageorgiou, Bart J Rijnders, Jarom Heijmans

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)

Abstract

BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalThe Journal of Infectious Diseases
Volume227
Issue number2
Early online date4 Aug 2022
DOIs
Publication statusPublished - 15 Jan 2023

Keywords

  • B-cell dysfunction
  • COVID-19
  • anti-SARS-CoV-2 hyperimmune globulin
  • plasma-derived antibody therapy
  • severely immunocompromised state

Cite this